Anna Skowrońska

4.0k total citations · 1 hit paper
37 papers, 2.6k citations indexed

About

Anna Skowrońska is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Anna Skowrońska has authored 37 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Genetics and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Anna Skowrońska's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Diet and metabolism studies (7 papers). Anna Skowrońska is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Diet and metabolism studies (7 papers). Anna Skowrońska collaborates with scholars based in United Kingdom, Poland and Germany. Anna Skowrońska's co-authors include Mabel Teng, Philip J. Johnson, Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Paul B.S. Lai, Shinji Satomura, Stephen L. Chan, Bruno Sangro and Mercedes Iñarrairaegui and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

In The Last Decade

Anna Skowrońska

36 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

2014 1.8k citations Philip J. Johnson, Sarah Berhane et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Anna Skowrońska

Since Specialization

Citations

This map shows the geographic impact of Anna Skowrońska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Skowrońska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Skowrońska more than expected).

Fields of papers citing papers by Anna Skowrońska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Skowrońska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Skowrońska. The network helps show where Anna Skowrońska may publish in the future.

Co-authorship network of co-authors of Anna Skowrońska

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Skowrońska. A scholar is included among the top collaborators of Anna Skowrońska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Skowrońska. Anna Skowrońska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Probiotics may be useful for drug-induced liver dysfunction in patients with depression – A secondary analysis of a randomized clinical trial 2024 ·Clinical Nutrition ESPEN ·(unknown), (unknown), (unknown), Anna Skowrońska, Dominik Strzelecki	4
2	The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver—A Secondary Analysis of the Pro-Demet Randomized Clinical Trial 2024 ·Nutrients ·(unknown), (unknown), Karolina H. Czarnecka, (unknown), (unknown), Anna Skowrońska, Dominik Strzelecki	3
3	Etiological factors of bloodstream infections in oncological Patients, who was hospitalized at the National Institute of Maria Skłodowska-Curie – National Research Institute in Warsaw in 2020-2022 2024 ·Przeglad Epidemiologiczny ·(unknown), Anna Skowrońska, (unknown), (unknown), (unknown), (unknown), (unknown)	0
4	Associations between intestinal fatty-acid binding protein and clinical and metabolic characteristics of depression 2024 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·(unknown), Karolina H. Czarnecka, (unknown), (unknown), (unknown), Anna Skowrońska, Ewa Brzeziańska‐Lasota, Dominik Strzelecki	3
5	The Influence of Probiotic Supplementation on the Severity of Anxiety and Depressive Symptoms; Function and Composition of Gut Microbiota; and Metabolic, Inflammation, and Oxidative Stress Markers in Patients with Depression—A Study Protocol 2023 ·Metabolites ·Anna Skowrońska, (unknown), (unknown), Dominik Strzelecki	7
6	The Influence of Probiotic Supplementation on Depression, Anxiety, and Stress Level, as well as Inflammation, Anthropometric and Metabolic Parameters in Patients with Depressive Disorders - preliminary results of an RCT 2023 ·European Psychiatry ·(unknown), Anna Skowrońska, (unknown), Dominik Strzelecki	1
7	PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results 2023 ·Nutrients ·(unknown), (unknown), Anna Skowrońska, Dominik Strzelecki	12
8	The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival 2022 ·Clinical Therapeutics ·Theresa Hydes, Daniel J. Cuthbertson, (unknown), Sarah Berhane, Mabel Teng, Anna Skowrońska, Pushpa Singh, (unknown), Abd A. Tahrani, Philip J. Johnson	10
9	The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation, and Oxidative Stress Parameters and Fecal Microbiota in Patients with Depression Depending on Metabolic Syndrome Comorbidity—PRO-DEMET Randomized Study Protocol 2021 ·Journal of Clinical Medicine ·(unknown), Anna Skowrońska, (unknown), Karolina H. Czarnecka, Igor Łoniewski, Karolina Skonieczna‐Żydecka, Dominik Strzelecki	12
10	Refeeding syndrome as treatment complication of anorexia nervosa 2018 ·Psychiatria Polska ·Anna Skowrońska, (unknown), Dominik Strzelecki	11
11	Accuracy of the European Thyroid Imaging Reporting and Data System (EU-TIRADS) in the valuation of thyroid nodule malignancy in reference to the post-surgery histological results 2018 ·Polish Journal of Radiology ·Anna Skowrońska, (unknown), (unknown), Witold Chudziński, (unknown), Michał Mazurkiewicz, Piotr Miśkiewicz, Tomasz Bednarczuk	20
12	Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification 2015 ·Cell Death and Disease ·G. Doreen te Raa, Perry D. Moerland, (unknown), (unknown), (unknown), Nadja Laddach, (unknown), Veronika Navrkalová, Martin Trbušek, Dieuwertje M. Luijks, Thorsten Zenz, Anna Skowrońska, Mels Hoogendoorn, Tatjana Stanković, M. H. van Oers, Eric Eldering, Arnon P. Kater	13
13	Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification 2015 ·Blood ·Doreen te Raa, Perry D. Moerland, (unknown), Ingrid A. M. Derks, Martin Lodén, Veronika Navrkalová, Martin Trbušek, Dieuwertje M. Luijks, Thorsten Zenz, Anna Skowrońska, Tatjana Stanković, Mels Hoogendoorn, Marinus H. J. van Oers, Eric Eldering, Arnon P. Kater	1
14	ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial 2014 ·Haematologica ·Matthew Rose‐Zerilli, Jade Forster, Helen Parker, Adrian G. Parker, Alfredo E. Rodríguez, Tracy Chaplin, Amy S. Gardiner, Andrew J. Steele, Andrew Collins, Bryan D. Young, Anna Skowrońska, Daniel Catovsky, Tatjana Stanković, David Oscier, Jonathan C. Strefford	46
15	The impact of SF3B1 mutations in CLL on the DNA-damage response 2014 ·Leukemia ·G. Doreen te Raa, (unknown), Veronika Navrkalová, Anna Skowrońska, Perry D. Moerland, (unknown), Ceri Oldreive, Hanneke N. Monsuur, Martin Trbušek, Jitka Malčíková, Martin Lodén, Carsten Geisler, Jennifer Hüllein, Alexander Jethwa, Thorsten Zenz, Šárka Pospı́šilová, Tatjana Stanković, Marinus H. J. van Oers, Arnon P. Kater, Eric Eldering	61
16	The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia 2013 ·Leukemia & lymphoma ·Tatjana Stanković, Anna Skowrońska	53
17	Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial 2012 ·Journal of Clinical Oncology ·Anna Skowrońska, Anton Parker, (unknown), Ceri Oldreive, Zadie Davis, Sue Richards, Martin J.S. Dyer, Estella Matutes, David González, A. Malcolm R. Taylor, Paul Moss, Peter Thomas, David Oscier, Tatjana Stanković	77
18	ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele 2011 ·Haematologica ·Anna Skowrońska, Belinda Austen, Jean Powell, Victoria Weston, David Oscier, Martin J.S. Dyer, Estella Matutes, Guy Pratt, Chris Fegan, Paul Moss, M.A. Taylor, Tatjana Stanković	26
19	[Micronuclei as markers of DNA damage in patients addicted to opioid drugs]. 2004 ·PubMed ·Anna Skowrońska, (unknown), (unknown)	1
20	Codex diplomaticus nec non epistolaris Silesiae 1963 ·Anna Skowrońska	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact